Healthcare Industry News: Tissue Removal System
News Release - July 27, 2009
John P. McDonough Joins Interlace Medical's Board of DirectorsFRAMINGHAM, Mass.--(HSMN NewsFeed)--Interlace Medical is pleased to announce that John P. McDonough has joined the company’s Board of Directors effective July 10th, 2009.
"John McDonough is one of the most successful and influential executives in New England, and Interlace Medical is pleased to have him join our board," stated Bill Gruber, President and CEO of Interlace Medical. "In addition to his many years of operational and new business development experience, John has been instrumental in driving market growth and adoption of minimally invasive technologies within the women’s health market space. His insights and knowledge in this area will benefit Interlace Medical as we launch the MyoSure(TM) Tissue Removal System into an underserved and growing market."
"Interlace and the MyoSure procedure will enable more physicians to treat symptomatic fibroids and provide women with alternatives to more invasive procedures. I am honored to join the Interlace Medical Board of Directors as the company prepares for market introduction of a critical product that will improve the lives of women around the world. Interlace Medical’s talented team and experienced Board of Directors has positioned the company for great success,” said Mr. McDonough.
Mr. McDonough currently serves as President and CEO of T2 Biosystems, a venture-backed medical diagnostics company developing a point-of-care platform based on magnetic resonance and nanotechnology. Prior to joining T2 Biosystems in 2007, John was President of Cytyc Development Corporation and was a member of the Senior Executive Team for Cytyc Incorporated from 2003-2007. Cytyc, a leading women's health technology company with revenue in excess of $750 million, was acquired by Hologic Incorporated in 2007 and Mr. McDonough was instrumental in leading the Cytyc-Hologic integration effort. In addition, John led all aspects of Cytyc’s acquisition and growth strategy including targeting acquisition candidates in strategic markets.
Mr. McDonough was also the Founder and CEO of Soundbite Communications, COO of Direct Hit Technologies, President and CEO of Workgroup Technology Corporation, President and CEO of Easel Corporation and served as a member of the high technology group at Deloitte & Touche.
According to “Women’s Health: US Markets for Benign Uterine Condition Management”, published by Medtech Insight, the number of fibroid treatments is increasing at an annual growth rate of 21.3%. Interlace Medical Inc. has developed the MyoSure Tissue Removal System which is currently pending 510k clearance. The MyoSure System is an easy-to-use, incision-less procedure that quickly and safely removes intrauterine fibroids and polyps, a common cause of abnormal uterine bleeding which afflicts over 10 million women in the United States. By developing cost effective, technologically advanced devices that improve patient care, reduce cost and provide procedural convenience to physicians, Interlace Medical addresses an ongoing need for safer, less invasive gynecology procedures.
For additional information visit www.interlacemedical.com.
Source: Interlace Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.